Giorgia Guglielmi
Plant compounds and gut microbiota activity influence how cancer drugs work and should be considered in treatment.
Tracking the oral microbiota can help identify ECC risk early and inform prevention strategies in children, even before visible signs of decay.
AceCel is a promising way to help manage obesity by targeting gut bacteria and metabolism together.
Nanoparticle-based approaches are a promising strategy for treating colorectal cancer.
Fungal metabolites such as FF-C1 may offer a new therapeutic approach for treating MAFLD and related conditions.
Certain barriers on the skin prevent easy colonization of new strains and specific life stages, such as adolescence, may be crucial for successful probiotic interventions.
Even small differences between strains of gut bacteria—often within the same species—can sway how these microbes interact with the human body and influence disease outcomes.
Genetic factors can influence tumor-associated microbes, offering insights into colorectal cancer progression and potential therapeutic targets.
TCA can help to manage IBD by supporting the gut barrier and influencing microbiota composition.
The findings of a recent study highlight the importance of early-life gut microbes in shaping lung health and add to evidence that microbiota composition can influence asthma risk.
